Moderna (MRNA) Accumulated Expenses (2017 - 2026)

Moderna (MRNA) has 10 years of Accumulated Expenses data on file, last reported at $1.9 billion in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $1.9 billion, up 91.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 91.01% YoY), and the FY2025 annual result was $1.4 billion, down 2.87% from the prior year.
• Accumulated Expenses rose to $1.9 billion in Q1 2026 per MRNA's latest filing, from $1.4 billion in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.2 billion in Q3 2023 and troughed at $987.0 million in Q2 2025.
• A 5-year average of $1.6 billion and a median of $1.5 billion in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses jumped 113.55% in 2022, then tumbled 38.13% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $2.1 billion in 2022, then fell by 14.42% to $1.8 billion in 2023, then fell by 20.63% to $1.4 billion in 2024, then dropped by 2.87% to $1.4 billion in 2025, then soared by 37.95% to $1.9 billion in 2026.
• Business Quant data shows MRNA's Accumulated Expenses at $1.9 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.2 billion in Q3 2025.